Peroxisome proliferator-activated receptor troglitazone

Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000 49(4) 539 17. 

Troglitazone is an example of the thiozolidinedione class of antidiabetic agents. It enhances insulin sensitivity in liver, muscle, and adipose tissue. Troglitazone promotes the conversion of non-lipid-storing preadipocytes to mature adipocytes (discussed later) with increased insulin sensitivity. The cellular target for the action of troglitazone, which functions as a transcription factor, is the nuclear receptor known as peroxisome proliferation-activated receptor-/ (PPAR-/). PPAR-/ upon binding... 

Enhancers of insulin action, such as peroxisome proliferator-activated receptor (PEAR) ligands [e.g., troglitazone (withdrawn from clinical use), pioglitazone, rosi-glitazone], retinoid X receptor (RXR) modulators, and protein tyrosine phosphatase IB (PTP IB) inhibitors... 

Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koef-fler HP (1998) Ligand for peroxisome proliferator-activated receptor y (troglitazone) has potent antitumor effects against human prostate cancer both in vitro and in vivo. Cancer Res 58 3344-3352... 

The antidiabetic thiazolidinedione activators of peroxisome proliferator-activated receptors (PPARs) include rosiglitazone (100, Avandia ), pioglitazone (Actos ) and troglitazone (Rezulin ), and all include a benzyl-linked thiazolidinedione ring which is constructed via a Knoevenagel condensation between thiazolidinedione 51 and a substituted benzaldehyde such as 98 under Cope conditions. ... 

---